Cryptobtc

Eli Lilly (NYSE:LLY) announced an aggressive expansion into the infectious disease prevention sector, entering into definitive agreements to acquire three distinct vaccine developers for a combined potential value of up to $3.83 billion in cash.

Aprea Therapeutics (NASDAQ:APRE) announced Wednesday that it ended the first quarter with $46.5 million in cash and cash equivalents, a sharp increase from the end of 2025.

ProMIS Neurosciences (NASDAQ:PMN) announced a transformational shift in its financial standing today, reporting that a massive private investment in public equity (PIPE) financing has secured the company’s clinical roadmap into 2027.

Organigram Global (NASDAQ:OGI) posted net revenue of $59.8 million for the quarter ended March 31, 2026, a 9% decrease from the same period last year.

Shaojing Tong, CFO at Chinese biotech firm RemeGen, discusses the company's first quarter results and shares his confidence in growth in the domestic market. The company's stock has outperformed all of its peers in the MSCI China Healthcare Index since the start of the year.

Jamey Millar, executive vice president, US operations of Novo Nordisk, reacts to Eli Lilly's once-daily weight-loss pill, called Foundayo, winning FDA approval on "Bloomberg The Close."

Temasek CEO Dilhan Pillay Sandrasegara says AI will not eliminate the need for software during a discussion with Bloomberg's Lisa Abramowicz at Bloomberg Invest.

For decades, Harvard has sought to develop land in Boston's Allston neighborhood, looking to turn the area into a science hub with innovative labs that could spur local economic growth. Now a perfect storm is brewing, one tied to real estate, biotechnology and the Trump administration, that is blowing the university's ambitious plans off course.

Novo Nordisk Chief Scientific Officer Martin Holst Lange discusses the recent clinical trial results of the company's weight loss obesity shot CagriSema, which delivered less weight loss than Eli Lilly's tirzepatide. Holst Lange also outlines Novo Nordisk's broader obesity treatment pipeline. He speaks on "Bloomberg Open Interest."